Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

387
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
387
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

390
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
390
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

769
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
769
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.2K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.2K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

986
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
986
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

790
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
790

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease.

Gut and liver·2026
Same author

Erratum: "Tract-specific white matter microstructure associated with early cognitive development in infants" [Neuroimage Rep 6 (2026) 100336].

Neuroimage. Reports·2026
Same author

Habitual Ultra-processed Food Intake Is Associated with Gut Dysbiosis and Pro-inflammatory Metabolite Profiles in Korean Patients with IBD.

Digestive diseases and sciences·2026
Same author

Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations.

Inflammatory bowel diseases·2026
Same author

Image Tracing of Inflammatory Intestinal Organoids via Computational Clearing.

Nanomaterials (Basel, Switzerland)·2026
Same author

Korean clinical practice guidelines for bowel preparation before colonoscopy.

Clinical endoscopy·2026

Related Experiment Video

Updated: Dec 29, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K

JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications.

Manasi Agrawal1, Eun Soo Kim1,2, Jean-Frederic Colombel1

  • 1Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York NY, USA.

Journal of Crohn'S & Colitis
|February 2, 2020
PubMed
Summary

Janus kinase inhibitors (JAKi) offer advantages for immune-mediated diseases like ulcerative colitis (UC). However, clinicians must carefully manage JAKi safety concerns, including thromboembolism and infections, with specific monitoring strategies.

Keywords:
Inflammatory bowel diseasesJAK inhibitorsadverse effectsclinical caredrug safetymonitoringpreventivetofacitinibulcerative colitis

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.1K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.4K

Related Experiment Videos

Last Updated: Dec 29, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.1K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.4K

Area of Science:

  • Immunology
  • Pharmacology
  • Gastroenterology

Background:

  • Janus kinase inhibitors (JAKi) are a novel class of small molecule drugs targeting inflammatory pathways.
  • Tofacitinib, a non-selective JAKi, is approved for moderate-to-severe ulcerative colitis (UC) refractory to tumor necrosis factor inhibitors (TNFi).
  • JAKi offer benefits like oral administration and rapid onset over traditional therapies.

Purpose of the Study:

  • To provide a practical guide for clinicians managing inflammatory bowel disease (IBD) patients on JAKi.
  • To highlight the safety considerations and monitoring strategies associated with JAKi use.
  • To discuss nuances in preventing and managing adverse effects of JAKi.

Main Methods:

  • This viewpoint synthesizes current knowledge on JAKi safety in IBD.
  • It reviews clinical data and expert recommendations for managing JAKi-related risks.
  • It addresses specific safety concerns including thromboembolism, infections, and hyperlipidemia.

Main Results:

  • JAKi, while effective, carry risks such as thromboembolism, infections, and hyperlipidemia.
  • Specific monitoring and preventive strategies are crucial for mitigating these risks.
  • Limited data exist for managing JAKi in special populations like pregnant or breastfeeding women, or those with a history of malignancy.

Conclusions:

  • Careful patient selection and vigilant monitoring are essential for safe JAKi use in IBD.
  • Ongoing research will further elucidate long-term safety implications and optimize JAKi therapy.
  • Clinicians need to be aware of JAK selectivity and potential gut-selective agents for future treatment paradigms.